Dr Toby Maher is a Consultant Respiratory Physician working on the Interstitial Lung Disease Unit at the Royal Brompton Hospital. He is also an honorary Senior Lecturer at Imperial College, London and holds an honorary Senior Research Associate post at University College London.
Dr Maher MB, MSc, PhD, MRCP qualified from Southampton Medical School in 1998. He trained in respiratory medicine at the Royal Brompton Hospital and completed an MSc in Respiratory Medicine (awarded with Distinction) at Imperial College, London. During his training he was awarded a Clinical Research Fellowship by the Wellcome Trust that enabled him to undertake a PhD researching the causes of Idiopathic Pulmonary Fibrosis.
Dr Maher is one of three consultants working on the Interstitial Lung Disease (ILD) Unit at the Brompton. The Brompton ILD Unit is dedicated to the diagnosis and treatment of patients with various forms of interstitial lung disease (this includes conditions such as idiopathic pulmonary fibrosis, sarcoidosis and lung disease associated with connective tissue disease). The unit is the only dedicated centre of its kind in the United Kingdom and is one of the largest ILD units in the world. The Brompton ILD unit was involved in early trials of the new anti-fibrotic drug pirfenidone, and now has in place a scheme for prescribing pirfenidone to individuals with mild to moderate IPF. Dr Maher currently oversees clinical trials within the unit.
In addition to his clinical work Dr Maher is Chair of the British Thoracic Society (BTS) specialist advisory group for rare (orphan) lung disease. He also sits on the council of the BTS and is Treasurer for the British Association for Lung Research. Dr Maher frequently lectures on topics related to pulmonary fibrosis and interstitial lung disease both in the UK and internationally. He is a Senior Associate Editor of the international respiratory journal Respirology.
Silvia D, Montgomery A, Sestini P, Souteriou H, Maher TM, Wells AU, Renzoni EA. Ambulatory oxygen in interstitial lung disease.Eur Resp J (In press)
Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Wells AU, Nicholsosn AG, Tetley TD, Laurant GJ, Chambers RC, McAnulty RJ. Reduced prostaglandin E2 in idiopathic pulmonary fibrosis contributes to disease pathogenesis by paradoxically reducing fibroblast but increasing epithelial apoptosis. AJRCCM 2010; 182:73-82
Maher TM. Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 2169.
Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs of Today. 2010; 46:473 - 482
Maher TM, Wells AU. Lost in translation: from animal models of pulmonary fibrosis to human disease. Respirology 2009; 14: 915 – 916.
- Krupiczojc MA, Scotton CJ, Koenigshoff M, Lee YCG, Kaminski N, Morser J, Post JM, Maher TM,Nicholson AG, Moffatt JD, Laurent GJ, Eickelberg O, Chambers RC. Local extrahepatic upregulation of coagulation factor X: potential novel role in fibrotic lung disease. J Clin Invest 2009; 119: 2550 – 2563.
- Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins RG.Lysophosphatidic acid induces avβ6 integrin-mediated TGF-β activation via the LPA2 receptor and the small G protein Gαq. Am J Path 2009: 174; 1264 -1279.
- Mordechai Y, Gat M, Myer JJ, Freidman PJ, Maher TM, Madison JM. Vibration response imaging technology in healthy subjects. AJR Am J Roentgenol 2008: 191; 845 - 852.
Intuition Communication Ltd bears no responsibility for information
published on this website, which concerns or relates to advertisers and
their products and services. Read Disclaimer in full.